Premarket Biotech Digest – RDUS Reports Positive Results, RHHBY Investigates Case, QDEL Receives Japanese Approval

Aerie Pharmaceuticals announced positive results from its Phase 3 clinical trial, Mercury 2. Puma Biotechnology is reprorted to have received 12-4 approval from an FDA advisory committee for its experimental breast cancer drug.